Anixa Biosciences, Inc. (ANIX) Investor Relations Documents

Anixa Biosciences, Inc. (ANIX) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2026-04-02. Read in-app with summaries. First-party data.

Fact Sheet: Anixa Biosciences is a clinical-stage oncology company developing CER-T therapies and cancer vaccines, highlighted by positive Phase 1 breast cancer vaccine data.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-14Press releaseAnixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
2026-07-14Press releaseAnixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology
2026-07-06Press releaseAnixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
2026-07-06Press releaseAnixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
2026-06-29Press releaseAnixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
2026-06-29Press releaseAnixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040
2026-06-26Press releaseAnixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observa
2026-06-26Press releaseAnixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observa
2026-06-11Press releaseAnixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences&a
2026-06-11Press releaseAnixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences&a
2026-06-01Press releaseAnixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice
2026-06-01Press releaseAnixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice
2026-05-11Press releaseAnixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer C
2026-05-11Press releaseAnixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer C
2026-05-01Press releaseAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
2026-05-01Press releaseAnixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
2026-04-29Press releaseAnixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
2026-04-29Press releaseAnixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
2026-04-22Press releaseAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell &
2026-04-22Press releaseAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell &
2026-04-09Press releaseAnixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovator
2026-04-09Press releaseAnixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conferen
2026-04-09Press releaseAnixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovator
2026-04-07Press releaseAnixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
2026-04-07Press releaseAnixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
2026-04-06Press releaseAnixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
2026-04-02Fact sheetFact Sheet
2026-04-01Press releaseAnixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for c
2026-04-01Press releaseAnixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for c
2026-03-30Press releaseAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologi
2026-03-30Press releaseAnixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologi
2026-03-12Press releaseAnixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
2026-03-12Press releaseAnixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
2026-03-09Press releaseAnixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering
2026-03-09Press releaseAnixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering
2026-03-02Press releaseAnixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical
2026-03-02Press releaseAnixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical
2026-02-23Press releaseAnixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research
2026-02-23Press releaseAnixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research
2026-02-09Press releaseAnixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory A

ANIX overview · ANIX earnings · ANIX financials · ANIX KPIs · ANIX ownership · ANIX peers · ANIX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.